ReviewBMC endocrine disorders2016
Oxytocin and cardioprotection in diabetes and obesity.
Review in BMC endocrine disorders, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 59 citations in OpenAlex.
- The Qur'anic heart and converging evidence from contemporary cardiac science: From qalb to cardioception.Journal of Taibah University Medical Sciences · 2026Review
- Oxytocin varies across the life course in a sex-specific way in a human subsistence population.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- The Role of Oxytocin Neurons in the Paraventricular Nucleus in Chronic-Sleep-Deprivation-Mediated Abnormal Cardiovascular Responses.Current issues in molecular biology · 2025Article
- Exploring early DNA methylation alterations in type 1 diabetes: implications of glycemic control.Frontiers in endocrinology · 2024Article
- Article
- Effects of neprilysin and neprilysin inhibitors on glucose homeostasis: Controversial points and a promising arena.Journal of diabetes · 2023Review
- Association between Serum Oxytocin, Bone Mineral Density and Body Composition in Chinese Adult Females.Medicina (Kaunas, Lithuania) · 2022Article
- Oxytocin and Related Peptide Hormones: Candidate Anti-Inflammatory Therapy in Early Stages of Sepsis.Frontiers in immunology · 2022Review
- Complementary Role of Oxytocin and Vasopressin in Cardiovascular Regulation.International journal of molecular sciences · 2021Review
- Targeting the Oxytocinergic System: A Possible Pharmacological Strategy for the Treatment of Inflammation Occurring in Different Chronic Diseases.International journal of molecular sciences · 2021Review
- HJournal of clinical medicine · 2021Article
- Sex Differences in MicroRNA Expression and Cardiometabolic Risk Factors in Hispanic Adolescents with Obesity.The Journal of pediatrics · 2021Article
- Cardiovascular protective properties of oxytocin against COVID-19.Life sciences · 2021Review
- Confirmation of the cardiac safety of nolasiban in a randomised cohort of healthy female volunteers.Scientific reports · 2021Article
- Is Oxytocin "Nature's Medicine"?Pharmacological reviews · 2020Review
- Oxytocin's anti-inflammatory and proimmune functions in COVID-19: a transcriptomic signature-based approach.Physiological genomics · 2020Article
- The Interaction of the Endogenous Hydrogen Sulfide and Oxytocin Systems in Fluid Regulation and the Cardiovascular System.Antioxidants (Basel, Switzerland) · 2020Article
- Review
- Article
- Vasopressin & Oxytocin in Control of the Cardiovascular System: An Updated Review.Current neuropharmacology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oxytocin (OT) emerges as a drug for the treatment of diabetes and obesity. The entire OT system is synthesized in the rat and human heart. The direct myocardial infusion with OT into an ischemic or failing heart has the potential to elicit a variety of cardioprotective effects. OT treatment attenuates cardiomyocyte (CMs) death induced by ischemia-reperfusion by activating pro-survival pathways within injured CMs in vivo and in isolated cells. OT treatment reduces cardiac apoptosis, fibrosis, and hypertrophy. The OT/OT receptor (OTR) system is downregulated in the db/db mouse model of type 2 diabetes which develops genetic diabetic cardiomyopathy (DC) similar to human disease. We have shown that chronic OT treatment prevents the development of DC in the db/db mouse. In addition, OT stimulates glucose uptake in both cardiac stem cells and CMs, and increases cell resistance to diabetic conditions. OT may help replace lost CMs by stimulating the in situ differentiation of cardiac stem cells into functional mature CMs. Lastly, adult stem cells amenable for transplantation such as MSCs could be preconditioned with OT ex vivo and implanted into the injured heart to aid in tissue regeneration through direct differentiation, secretion of protective and cardiomyogenic factors and/or their fusion with injured CMs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.